Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.54 |
| ▸ | ITGAV | P06756 | 6/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.54 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.54 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.54 |
| ▸ | ITGA8 | P53708 | 2/20 | 0.54 |
| ▸ | GPR139 | Q6DWJ6 | 10/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14532475 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL3835287 | 0.86 | GPR139 (0.48) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| Trifluoroacetic Acid SCHEMBL3835291 | 0.84 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| Hydrochloric Acid SCHEMBL7138995 | 0.81 | ITGB3 (0.54) | ITGB3ITGAVITGA2BKMT2A | |
| Hydrochloric Acid SCHEMBL7139002 | 0.81 | ITGB3 (0.54) | ITGB3ITGAVITGA2BKMT2A | |
| SCHEMBL3835347 | 0.80 | GPR139 (0.52) | ITGB3ITGAVITGB1ITGA5GPR139 | |
| SCHEMBL14501720 | 0.80 | GPR139 (0.72) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| Trifluoroacetic Acid SCHEMBL6773199 | 0.79 | ROCK2 (0.42) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6778499 | 0.77 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL242674 | 0.77 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | ITGB3 2/4885ITGAV 1/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.